ConductScience.org, home

Paper8534872

The clinical experience with antiangiogenic agents.

Marshall JL and 1 other. Breast Cancer Res Treat, 1995. Cited by 13 papers, by iCite.

Cite this record

ConductScience Library. The clinical experience with antiangiogenic agents. Papers, record 8534872. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8534872

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The clinical experience with antiangiogenic agents.
PubMed
Journal
Breast Cancer Res Treat
PubMed
Year
1995
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
0.36
iCite
Revised in PubMed
2019-09-05
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Marshall JLJ L
2Hawkins MJM J

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Neovascularization, PathologicMajor topic
Clinical Trials as Topic
Humans

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
12710192Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a.N Engl J Med1989https://conductscience.org/library/papers/2710192PubMed
28468719Suramin, an active drug for prostate cancer: interim observations in a phase I trial.J Natl Cancer Inst1993https://conductscience.org/library/papers/8468719PubMed
38270611Antitumor effects of GBS toxin: a polysaccharide exotoxin from group B beta-hemolytic streptococcus.J Cancer Res Clin Oncol1993https://conductscience.org/library/papers/8270611PubMed
47509184Treatment of choroidal neovascularisation in age-related macular degeneration with interferon alfa-2a and alfa-2b.Br J Ophthalmol1993https://conductscience.org/library/papers/7509184PubMed
51279186Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals.J Natl Cancer Inst1992https://conductscience.org/library/papers/1279186PubMed
61991638Impaired sulphation of phenol by the colonic mucosa in quiescent and active ulcerative colitis.Gut1991https://conductscience.org/library/papers/1991638PubMed
71279332Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.Lancet1992https://conductscience.org/library/papers/1279332PubMed
81489383Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.N Engl J Med1992https://conductscience.org/library/papers/1489383PubMed
93958767Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon.J Clin Oncol1986https://conductscience.org/library/papers/3958767PubMed
107513432Thalidomide is an inhibitor of angiogenesis.Proc Natl Acad Sci U S A1994https://conductscience.org/library/papers/7513432PubMed
117505321The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis.J Pediatr Surg1993https://conductscience.org/library/papers/7505321PubMed
121882952Interferon alpha 2a for treatment of age-related macular degeneration.Am J Ophthalmol1991https://conductscience.org/library/papers/1882952PubMed
137707422Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4.J Natl Cancer Inst1995https://conductscience.org/library/papers/7707422PubMed
142570269Treatment of haemangioendotheliomas with alpha interferon.Lancet1989https://conductscience.org/library/papers/2570269PubMed
152926472Suramin: an anticancer drug with a unique mechanism of action.J Clin Oncol1989https://conductscience.org/library/papers/2926472PubMed
1614296026CLINICAL EXPERIENCES WITH THALIDOMIDE IN PATIENTS WITH CANCER.Clin Pharmacol Ther1965https://conductscience.org/library/papers/14296026PubMed
171375283Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.J Clin Oncol1992https://conductscience.org/library/papers/1375283PubMed
182463087The sulfated polysaccharide-peptidoglycan complex potently inhibits embryonic angiogenesis and tumor growth in the presence of cortisone acetate.Carbohydr Res1988https://conductscience.org/library/papers/2463087PubMed
196192498Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone.Science1983https://conductscience.org/library/papers/6192498PubMed
202161094Suramin-induced polyneuropathy.Neurology1990https://conductscience.org/library/papers/2161094PubMed

See all 37 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
24477603
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.
Cancer Chemother Pharmacol2014https://conductscience.org/library/papers/24477603PubMed
9881776Structure-function relations of heparin-mimetic sulfated xylan oligosaccharides: inhibition of human immunodeficiency virus-1 infectivity in vitro.Glycoconj J1998https://conductscience.org/library/papers/9881776PubMed
9195284Development of angiogenesis inhibitors for cancer therapy.Invest New Drugs1997https://conductscience.org/library/papers/9195284PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8534872

GET https://conductscience.org/api/papers/v1/8534872/references?page=2